1. Home
  2. CXE vs CRDF Comparison

CXE vs CRDF Comparison

Compare CXE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS High Income Municipal Trust

CXE

MFS High Income Municipal Trust

HOLD

Current Price

$3.79

Market Cap

120.1M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.99

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXE
CRDF
Founded
1989
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.1M
130.7M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
CXE
CRDF
Price
$3.79
$1.99
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
72.4K
678.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.36%
N/A
EPS Growth
N/A
27.37
EPS
0.07
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$54.43
N/A
Revenue Growth
N/A
49.61
52 Week Low
$3.38
$1.48
52 Week High
$3.88
$4.56

Technical Indicators

Market Signals
Indicator
CXE
CRDF
Relative Strength Index (RSI) 48.86 54.12
Support Level $3.66 $1.51
Resistance Level N/A $2.05
Average True Range (ATR) 0.05 0.13
MACD -0.01 0.06
Stochastic Oscillator 33.33 89.11

Price Performance

Historical Comparison
CXE
CRDF

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: